Company news
Zhejiang Jianfeng Group Co. Ltd. news in 2026
Zhejiang Jianfeng Group Co. Ltd.'s news releases, calls and decks from 2026, newest first.
(600668)"Zhejiang Jianfeng Group Co., Ltd."Announcement on Convening the Q3 2026 Performance Briefing
November 5, 2026
(600668)"Zhejiang Jianfeng Group Co., Ltd."Report for Q3 2026
October 28, 2026
(600668)"Zhejiang Jianfeng Group Co., Ltd."Announcement on Key Operating Data for the First Three Quarters of 2026
October 28, 2026
(600668)"Zhejiang Jianfeng Group Co., Ltd."Announcement on Abnormal Fluctuations in Stock Trading
October 16, 2026
(600668)"Zhejiang Jianfeng Group Co., Ltd."Announcement on Progress of Project Investment by a Controlled Subsidiary
October 11, 2026
Announcement on the Subsidiary's Receipt of the European CEP for Chemical API
September 24, 2026
Announcement on Progress in Providing Guarantee for Controlled Subsidiary
September 22, 2026
Announcement on the Subsidiary's Receipt of the Approval Notice for the Marketing Application of a Chemical API
September 1, 2026
Announcement on Resolutions of the 18th Meeting of the 12th Board of Directors
August 30, 2026
Zhe Jiang Jian Feng Group Co., Ltd.: Announcement on the Proposed Winning Bid of Subsidiary in the National Centralized Drug Procurement
August 3, 2026
Zhe Jiang Jian Feng Group Co., Ltd.: Announcement on Acquisition of Drug Registration Certificate by a Subsidiary
July 24, 2026
Zhe Jiang Jian Feng Group Co., Ltd.: Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
July 17, 2026
Zhe Jiang Jian Feng Group Co., Ltd.: Announcement on Expected Loss in Semi-annual Performance for 2026
July 14, 2026
Zhe Jiang Jian Feng Group Co., Ltd.: Announcement on Inclusion of the Subsidiary's Products in the "National Essential Medicines List (2026 Edition)"
July 10, 2026
Zhe Jiang Jian Feng Group Co., Ltd.: Announcement on Implementation of Dividend Distribution for 2025
July 2, 2026
Zhe Jiang Jian Feng Group Co., Ltd.: Announcement on Subsidiary Obtaining the Approval Notice for Drug Supplementary Application
June 30, 2026
Announcement on Obtaining Drug Registration Certificate by Subsidiary
June 25, 2026
Announcement on Overdue Financial Assistance Provided by a Subsidiary
June 17, 2026
Announcement on Resignation of Directors
May 19, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
May 12, 2026
Announcement on Subsidiary Obtaining Approval for Marketing of Chemical APIs
May 8, 2026
Report for Q1 2026
April 28, 2026
Announcement on Withdrawal of Drug Registration Application by the Subsidiary
April 24, 2026
Announcement on Implementation Result of Shares Repurchase and Share Changes
April 20, 2026
Notice on Convening the 2025 Annual General Meeting
April 13, 2026
Announcement on Progress in Repurchasing Shares through Call Auction
April 1, 2026
Announcement on Subsidiary Obtaining a Notice of Disapproval for the Drug Marketing Authorization Application
March 19, 2026
Earnings Preannouncement for 2025
January 27, 2026
Announcement on Withdrawal of Clinical Trail Application for Drug Registration by Subsidiary
January 15, 2026